Background Rheumatoid arthritis (RA) is an inflammatory joint disorder, the progression of which leads to the destruction of cartilage and bone. Wnt signaling pathway act several important biological functions, such as cell differentiation, embryonic development, limb development and joint formation. Accumulated evidence has suggested that this signaling pathway plays a key role in the FLS activation, bone resorption and joint destruction in RA. Objectives The purpose of this study was to investigate the activity of Wnt/β-catenin pathway in collagen-induced arthritis (CIA) in rats, and to research the therapeutic effect of resveratrol in this arthritis model. Methods Thirty Wistar albino female rats were randomized to 3 groups (n=10 in each group): Group-I as the control group, Group-II as the arthritis (sham) group, and Group-III as the Resveratrol group. Arthritis was induced by intradermal injection of chicken type II collagen combined with incomplete Freund's adjuvant. One day after the onset of arthritis, resveratrol (20 mg/kg/day) was given via oral gavage, until they were killed on day 29. Animals were sacrificed at the 15th day after the onset of arthritis. The paws of the rats were obtained for further analysis. Perisynovial inflammation and cartilage-bone destruction were determined histopathologically in the paws. Tissue Wnt-5a, axin-2, DKK1, mitogen-activated protein kinase (MAPK), Src tyrosine kinase and signal transducer and activator of transcription-3 (STAT3) mRNA expressions were determined by real-time polymerase chain reaction (RT-PCR). Results Arthritis was clinically developed at 12 to 13 days after the injection of collagen (Fig. 1a). The 29th day scores were decreased in the paricalcitol and pyrvinium groups compared to the own 13th day score (pConclusions The present study shows that Wnt signaling pathway is active in CIA model. Resveratrol inhibits Wnt pathway and ameliorates CIA. Zou Y, et al. Mol Med Rep. 2015;12(5):7221–6. Liu H, et al. Stem Cells Int. 2016;2016:2524092. Kotha A, et al. Mol Cancer Ther. 2006;5(3):621–9. Zhong LX, et al. J Ovarian Res. 2015;8:25. Acknowledgement None Disclosure of Interest None declared